Avid Bioservices to be sold to private equity firms for $1.1Bnews2024-11-07T13:29:18+00:00November 7th, 2024|Endpoints News|
Catalent touts customer confidence ahead of Novo deal, but misses revenue estimatesnews2024-11-05T18:17:43+00:00November 5th, 2024|Endpoints News|
Nektar divests manufacturing site and reagent arm for $90M news2024-11-05T12:03:51+00:00November 5th, 2024|Endpoints News|
Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3news2024-11-05T11:30:59+00:00November 5th, 2024|Endpoints News|
European Commission marks Dec. 6 for Novo-Catalent deal decisionnews2024-11-04T10:58:13+00:00November 4th, 2024|Endpoints News|
Baxter pulls IV products out of China to shift supply to the USnews2024-11-01T11:59:38+00:00November 1st, 2024|Endpoints News|
WuXi in ‘early stages’ of CGT business review; Lonza exec becomes AGC Bio CEOnews2024-10-31T16:15:12+00:00October 31st, 2024|Endpoints News|
Following March inspection, Novo Nordisk’s semaglutide manufacturing facility cited by FDAnews2024-10-29T19:38:06+00:00October 29th, 2024|Endpoints News|
MilliporeSigma invests €70M to triple ADC manufacturing at US site news2024-10-29T17:25:48+00:00October 29th, 2024|Endpoints News|
WuXi AppTec is still signing on new clients despite Biosecure threatnews2024-10-28T18:26:16+00:00October 28th, 2024|Endpoints News|
